Aarkstore Evolution of Technologies for Therapeutic Antibodies From mAbs to Biosimilars

1. Evolution of Technologies for Therapeutic Antibodies-From mAbs to Biosimilars Antisense therapy is a form of treatment for genetic disorders or infections. When the genetic sequence of a particular gene Gene therapy is the therapeutic delivery of nucleic acid polymers into a patient's cells as a drug to treat disease. Gene therapy could be a way to fix a genetic problem at its source. For More Information Visit : www.aarkstore.com For More Information Visit : www.aarkstore.com

2. Summary Scope of reportThe scope of the report is to highlight and gauge existing technologies in theproduction of therapeutic mAbs. The report also discusses key insights oninterchangeability and substitution of therapeutic antibodies and biosimilars.Further, there is also an assessment of the current drivers and restraints that affectthe uptake of biosimilars.The report answers key questions that are paramount for understanding thetechnologies involved in the production of therapeutic antibodies, such as:• What are the various types of monoclonal therapeutic antibodies?• Why is there a need for alternate forms of therapeutic antibodies?• What is the likely future direction for research in the development andmanufacture of monoclonal antibodies?• What are the key features of a genetically modified mouse for antibodyproduction?• How do ethical concerns drive the direction of research of futuremonoclonal antibodies?• What are the crucial features in establishing biosimilarity?• Is interchangeability between innovator monoclonal antibodies andbiosimilars ever achievable?• What are the limitations in the technologies used to evaluate the extents ofbiosimilarity? For More Information Visit : www.aarkstore.com

3. Why should you buy this report: The idea of using antibodies for therapy is about a century old. The successfulproduction of antibodies has always been stalled by challenges likeimmunogenicity, scaling to industry level production, microheterogenity,regulatory approvals and pricing. This report will help stakeholders to understandprevailing technologies and their merits and limitations. It discusses:• Technological deterrents encountered so far and the successfulstrategies to neutralize these• The contemporary situation and forthcoming prospects of existingtechnologies• The stages of the product pipeline that enterprises are centring on forsuccess• Ethical and regulatory considerations that set the path for the future For More Information Visit : www.aarkstore.com

4. Table of Content 1 INTRODUCTION 71.1 Study goals and objectives 71.2 Intended audience 7 2 SUMMARY103 TYPE OF ANTIBODIES CURRENTLY DEVELOPED 113.1 Antiserums 113.2 Targeted therapies 12 4 TECHNOLOGY AND TECHNOLOGICAL PLATFORMS204.1 Hybridoma technology 204.2 Genetically engineered antibodies 224.2.1 Genetically engineered mouse 23 5 MAJOR BIOSIMILAR ANTIBODIES IN DEVELOPMENT 335.1 Biosimilars: Originators vs Biosimilars 335.1.1 Challenges in establishing biosimilarity 33 6 CONCLUSION547 APPENDIX567.1 Adjuvants and their properties 567.2 Bibliography 58 For More Information Visit : www.aarkstore.com

5. List of Tables Table 1: Latest developments in upstream technologies 16 Table 2: Novel antibody-like technology platforms 17 Table 3: Latest development in formulations and drug delivery systems 19 Table 4: Overview of various analytical tools available that can be used for examination of various parameters during comparability studies 37 Table 5: Various proposed cross-over designs 39 Table 6: Various companies into biosimilar development with 41 Table 7: List of commonly used adjuvants and their properties 56 For More Information Visit : www.aarkstore.com

6. List of Figures • Figure 1: Timeline for technological developments in antibody based therapy starting with antiserum therapy to new age biologics 11 • Figure 2: Representation of the various steps involved in the Hybridoma technology 21 • Figure 3: Representation of chimeric and humanized mAbs 24 • Figure 4: Methodology for production of Xenomouse 26 • Figure 5: Cartoon representation of different N-linked glycosylations in human antibodies comprising sugars such as fucose, galactose 28 • Figure 6: Mechanism of action by adjuvants 31 • Figure 7: Why is achieving biosimilarity difficult? 35 • Figure 8: Cartoon representation of existing analytical techniques 38 • Figure 9: Depiction of investments of pharmaceuticals 40 • Figure 10: Country wise status of regulatory guidelines 48 • Browse full report Or Sample Request @ • http://www.aarkstore.com/biotechnology/117430/evolution-of-technologies-for-therapeutic-antibodiesfrom-mabs-to-biosimilars For More Information Visit : www.aarkstore.com

7. Related Reports • EDS, WDS, EBSD, Micro-XRF Instruments Market by Product, by Application (Energy, Defense, Metals, Medical, Research, Agriculture, Nanotechnology, Electronics, Biotechnology, Automotive, Pharmaceutical, Oil and Gas) - Global Forecasts to 2019 • US Enzyme-Linked Immunosorbent Assay(ELISA) Industry 2015 Market Research Report • Global RNAi for Therapeutic Industry 2015 Market Research Report • Global Prepacked Chromatography Columns Industry 2015 Market Research Report • Global Next-Generation Biologics Industry 2015 Market Research Report For More Information Visit : www.aarkstore.com

8. Follow Us https://www.facebook.com/aarkstoredotcom https://twitter.com/aarkstore https://plus.google.com/+Aarkstoredotcom/posts https://www.linkedin.com/company/aarkstore-enterprise For More Information Visit : www.aarkstore.com

9. Contact Us Office Address Office No. - 809, 8th Floor,B-Wing, Mahaavir Icon, Plot No.- 89 & 90, Sector-15,CBD-Belapur, Navi Mumbai – 400614, Maharashtra, India. Mail us at contact@aarkstore.com 24/7 Online Support: +91 9987295242 General Inquiries : +91 - 22 2756 4953 For More Information Visit : www.aarkstore.com